When considering the tissue inhibitor RECK, statistically significant differences were observed between B-cell and T-cell lymphomas, and between T-cell lymphomas and healthy controls (p<0.05). The gene discussed is RECK; the disease is T-cell non-Hodgkin lymphoma.